Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme

E-ISSN： 1875-533x|16|23|2943-2951

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.23, 2009-08, pp. : 2943-2951

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 11-18

Bentham Science Publishers

Access to resources Recommend Favorite

CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 3, 2007-03 ,pp. : 253-273

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl-Peptidase IV (DPP IV/CD26)-Activated Prodrugs: A Successful Strategy for Improving Water Solubility and Oral Bioavailability

Current Medicinal Chemistry, Vol. 22, Iss. 8, 2015-03 ,pp. : 1041-1054

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

By Ahrén Bo

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 4, 2008-12 ,pp. : 593-607

Informa Healthcare

Access to resources Recommend Favorite

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences

By Baetta Roberta Corsini Alberto

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1441-1467

Adis International

Access to resources Recommend Favorite